Considering the importance of ADP ribosylation on the function of BORIS and the complex catalysis mechanism by multiple PARPs, the inhibition of BORIS by PARP inhibitors for cancer treatment will not be logical or efficient. This evidence concerns the gene PARP1 and cancer.